GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Baron Funds Comments on Grifols SA

August 30, 2012 | About:
Holly LaFon

Holly LaFon

255 followers
From Baron Funds' second quarter commentary:

Grifols SA (GRFS) manufactures and sells plasma derivative healthcare products to hospitals and physicians globally. Grifols' NASDAQ-traded ADR increased over 24% during the quarter. Grifols' plasma proteins are an essential medical treatment for patients with primary immune deficiency, neurological diseases or hemophilia. Few companies can manufacture these treatments with a high degree of quality and consistency. Healthy demand for the product, coupled with a strong pricing environment, helped Grifols during the quarter.We continue to believe that Grifols will generate strong synergies from its 2011 acquisition of U.S.-based Talecris, and that Grifols will become significantly more profitable going forward. (Aaron Wasserman)

Rating: 3.3/5 (8 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK